via Tokyo University of Science
Scientists modified “mesenchymal stem cells” to carry anti-cancer drugs and deliver them to target cancers
Targeting drugs to cancer tissues is a major challenge in cancer treatment. Mesenchymal stem cells (MSCs) are known for their ability to find and target tumor cells in the body, but using MSCs for drug delivery has been tricky, because upon loading with drugs, MSCs lose their viability and migratory ability. Now, researchers from Tokyo University of Science have successfully modified MSCs to deliver large quantities of anti-cancer drugs in a targeted manner to developing cancer cells.
As humans evolve, cancer also evolves in parallel, making the race for finding efficient treatment methods for cancer patients challenging and constant. In addition to designing drugs for treatment, the delivery of these drugs to targeted organs is also a major challenge faced by the cancer research community.
Many research groups have tried to develop techniques to efficiently deliver anti-cancer drugs to tumors. An interesting way utilizes a distinct group of cells in our body, the mesenchymal stem cells (MSCs), which have a special ability to find and move towards tumors. This means that theoretically, we can load these “tumor-homing” MSCs with anti-cancer drugs and use them to hinder cancer progression. However, pilot studies show that the anti-cancer drug loading capacity of MSCs is limited, and they tend to lose their ability to target and reach tumor cells upon drug loading.
In a recent study published in Journal of Controlled Release, researchers from Japan, led by Dr. Kosuke Kusamori and Professor Makiya Nishikawa from Tokyo University of Science, sought to find out how to modify MSCs to bypass these problems. Dr. Kusamori, Assistant Professor in the University’s Department of Pharmacy says, “We wondered if the answer to our dilemma of modifying mesenchymal stem cells with an anticancer drug was to exploit the property of mesenchymal stem cells to accumulate in tumor tissues.”
Using the well-known “avidin-biotin complex” (ABC) method, the researchers used liposomes-cellular lipid bags popularly used as drug delivery systems-to carry the anti-cancer drug doxorubicin (DOX) to the surface of specific mouse MSCs. They named these lipid bags carrying DOX “DOX-Lips.”
The researchers found that the MSCs loaded with DOX-Lips could carry and selectively target mouse colon cancer cells growing in artificial cultures in the lab. These modified MSCs could not only carry a significant amount of the drug, but also efficiently deliver it inside the target cancer cells. To test if this feature is replicated in a living system, they used a mouse model with skin and lung cancer. They found that in both cases, DOX-Lips were able to efficiently reach cancer cells and release the drug into the cytoplasm of the cancer cells. The researchers concluded that the modified MSCs could completely suppress tumor growth in mouse models.
There are several advantages to this new method. First, the process is relatively faster than previously known methods. As Yukiya Takayama, a doctoral student in Professor Nishikawa’s lab and a co-author of the study observes, “The relatively short duration of the ABC method made it possible to quickly modify the cell surface with DOX-Lips and avoid cell damage.”
Second, this method did not affect the process of cell attachment to cancer cells, thereby ensuring maximum efficiency in drug delivery. Third, contrary to previous observations that lipid bags of only a certain size can be used to deliver drugs, this new study suggests that the size of the lipid bags very likely does not affect drug delivery; this finding can be exploited to deliver many different doses of drugs as well.
The combination of the ABC method and the use of Lips thus seems to be the answer to the researchers’ dilemma. Professor Nishikawa is excited about these results. “We have succeeded in developing a new targeted cancer therapy,” he observes. “Mesenchymal stem cells can migrate to brain tumors and minute cancer lesions that are otherwise inaccessible to conventional drug delivery systems. Our method may thus be effective against intractable cancers,” Nishikawa says.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Modified stem cells
- New prototype that regenerates stem cells may repair IPF scarring
Researchers developed NZ-97, an inhalable drug that stimulates the growth of stem cells in the lungs, potentially repairing scarring in IPF.
- Accessible Cell Therapies for Alzheimer's and Parkinson's Disease
Researchers have now potentially advanced the accessible personalized cell-based therapies for Alzheimer's and Parkinson's diseases.
- Rat neuron injection lets mice that can’t smell sniff out cookies
Mice that had been genetically modified to lack the ability to smell could sniff out hidden cookies when sensory neurons from rats were grown in their brains ...
- 8 of the most expensive drugs in biopharma: Unraveling the costliest medications
Find out what the ten most expensive drugs in the world currently are, as several gene therapies top the list.
- New device improves stem cell generation and chance for accessible Alzheimer's cell therapy
Researchers in Sweden say they have improved on a technique for converting regular skin cells into neural stem cells—an advance that they say helps close the gap for accessible personalized cell-based ...
Go deeper with Google Headlines on:
Modified stem cells
[google_news title=”” keyword=”modified stem cells” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Mesenchymal stem cells
- Claris Bio's journey toward treating neurotrophic keratitis
David Hutton, Managing Editor of Ophthalmology Times sat down with Claris Bio CEO, Clarke Atwell, to discuss the company's path toward developing treatment for neurotrophic keratitis.
- Nanoscope Therapeutics Appoints New Chief Medical Officer
Dallas-based Nanoscope said Dr. Allen C. Ho will help define the strategy of developing its gene mutation-agnostic therapies. Ho is attending surgeon and director of retina research at Wills Eye ...
- Therapeutic potential of human umbilical cord-derived mesenchymal stem cells in Crohn’s disease
Whether human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) could heal luminal ulcers in Crohn’s disease.
- The murky, unregulated world of anti-ageing stem cell therapy
Stem cells are the new focal point of the rich and famous with Hollywood A-listers reportedly spending tens of thousands of pounds each year on expensive therapies offered by private longevity clinics ...
- Stem Cell Magic: Scientists Unveil New Superhero for Healing Diabetes Wounds
Researchers unveiled a novel therapy for diabetic wound healing. The new research highlights the use of exosomal miR-4645-5p from hypoxic bone marrow mesenchymal stem cells (BMSCs) to significantly ...
Go deeper with Google Headlines on:
Mesenchymal stem cells
[google_news title=”” keyword=”mesenchymal stem cells” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]